



(51) International Patent Classification:

C12N 15/85 (2006.01) C12N 5/0789 (2010.01)
C12N 15/90 (2006.01) C12N 5/10 (2006.01)

(21) International Application Number:

PCT/US2024/032097

(22) International Filing Date:

31 May 2024 (31.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/505,647 01 June 2023 (01.06.2023) US

(71) Applicant: **GRAPHITE BIO, INC.** [US/US]; 201 Haskins Way, Suite 210, South San Francisco, California 94080 (US).

(72) Inventors: **LAHIRI, Premanjali**; c/o Graphite Bio, Inc., 201 Haskins Way, Suite 210, South San Francisco, California 94080 (US). **LORD, Daniel**; c/o Graphite Bio, Inc., 201 Haskins Way, Suite 210, South San Francisco, California 94080 (US). **SHAH, Meet**; c/o Graphite Bio, Inc., 201 Haskins Way, Suite 210, South San Francisco, California 94080 (US).

nia 94080 (US). **SKOWRONSKI, Jason**; c/o Graphite Bio, Inc., 201 Haskins Way, Suite 210, South San Francisco, California 94080 (US). **YUAN, Yue**; c/o Graphite Bio, Inc., 201 Haskins Way, Suite 210, South San Francisco, California 94080 (US).


(74) Agent: **COX, Ryan P.** et al.; SQUIRE PATTON BOGGS (US) LLP, 1841 Page Mill Road, Suite 150, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: METHODS FOR CLINICAL-SCALE PRODUCTION OF GENETICALLY MODIFIED PRIMARY CELLS

FIGURE 5



(57) Abstract: The processes provided herein utilize high-capacity gas-permeable cell culture and flow-through electroporation devices to transfect primary cells with gene-editing reagents under conditions which improve gene editing performance, cell yield and drug product (DP) quality attributes for cell therapy applications.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*